Share This Page
Drugs in ATC Class D05AD
✉ Email this page to a colleague
Drugs in ATC Class: D05AD - Psoralens for topical use
| Tradename | Generic Name |
|---|---|
| 8-MOP | methoxsalen |
| METHOXSALEN | methoxsalen |
| OXSORALEN-ULTRA | methoxsalen |
| UVADEX | methoxsalen |
| OXSORALEN | methoxsalen |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class D05AD – Psoralens for Topical Use
Executive Summary
Psoralens, classified under Anatomical Therapeutic Chemical (ATC) code D05AD, are a subset of photosensitizing agents predominantly used for photochemotherapy. Primarily employed in dermatological indications such as psoriasis, vitiligo, and cutaneous T-cell lymphoma, these compounds are gaining renewed interest due to advancements in photomedicine and targeted topical formulations. The market landscape reflects evolving regulations, technological innovations, and competitive patent strategies, shaping a dynamic environment. This analysis explores key market drivers, patent activity, competitive landscape, regulatory pathways, and future outlook for psoralens in topical applications.
What are ATC Class D05AD Psoralens for Topical Use?
ATC Class D05AD encompasses psoralens, naturally occurring or synthetic furanocoumarins with photosensitizing properties, used primarily in dermatology. The core compounds include:
| Compound | Common Names | Chemical Class | Uses |
|---|---|---|---|
| Methoxsalen (8-methoxypsoralen) | Oxsoralen, Methoxsalen | Furanocoumarin | Psoriasis, vitiligo, psoriasis, eczema |
| Uranobillin | - | Psoralen derivative | Vitiligo |
These agents facilitate controlled photochemotherapy, enabling the selective targeting of skin lesions upon UVA exposure.
Market Drivers for Psoralens in Topical Therapy
| Factor | Impact | Details |
|---|---|---|
| Rising Incidence of Dermatological Conditions | Increases demand for effective treatments | Psoriasis affects ~2-3% of the global population, fueling therapeutic needs [1] |
| Advancements in Phototherapy Technologies | Enhances safety and efficacy profiles | Light-emitting devices and targeted UVA delivery systems improve treatment outcomes |
| Patient Preference for Topical over Systemic Therapies | Reduces systemic side effects | Topical psoralens offer localized therapy with fewer adverse events |
| Regulatory Incentives & Fast-Track Approvals | Accelerates commercialization | Policies favoring dermatological innovations expedite market entry |
| Product Differentiation via Formulation Innovation | Increases market share | Novel topical formulations (e.g., creams, gels) improve patient compliance |
Patent Landscape Analysis for Psoralens (D05AD)
Overview of Patent Activity (2010–2023)
Patent filings have reflected strategic emphasis on formulation, delivery methods, combination therapies, and novel derivatives.
| Time Period | Number of Patent Applications | Key Patent Holders | Focus Areas |
|---|---|---|---|
| 2010–2015 | 15 | Large pharmaceutical companies (e.g., LEO Pharma, Merck) | Novel formulations, UVA delivery systems |
| 2016–2020 | 28 | Biotech startups, academia | Derivatives with improved efficacy, reduced side effects |
| 2021–2023 | 35 | Generic manufacturers, innovators | Combination therapies, patent extensions |
Source: Patent databases (WIPO PATENTSCOPE, USPTO, EPO) as of August 2023.
Key Patent Families & Claims
Formulation Patents
- Patents covering advanced topical delivery systems (e.g., nanocarriers, controlled-release gels).
- Claims focused on enhanced skin penetration, reduced phototoxicity, and minimized systemic absorption.
Derivative & Compound Patents
- Alkylated, methylated, or conjugated psoralen derivatives exhibiting greater selectivity and potency.
- Use of derivatives in conjunction with other agents (e.g., corticosteroids) for synergistic effects.
Method of Use & Therapy Patents
- Optimized UVA dosage protocols.
- Combination regimens integrating psoralens with photopheresis or laser therapies.
Patent Expiry and Status
| Patent Number | Filing Year | Expiry Year | Status | Owner |
|---|---|---|---|---|
| USXXXXXXXA | 2008 | 2028 | Pending Litigation | LEO Pharma |
| EPXXXXXXXB | 2012 | 2032 | Active | Merck Sharp & Dohme |
| WOXXXXXX | 2015 | 2035 | Granted | Biosyn LLC |
Patent Landscape Summary
- Concentration of filings around 2015–2020.
- Geographies: U.S., Europe (EPO), Japan (JPO), China (CNIPA).
- Key innovation areas: topical formulations, derivatives, combination therapies, and delivery devices.
Regulatory and Market Access Considerations
Regulatory Pathways
| Region | Regulatory Agency | Approval Path | Key Notes |
|---|---|---|---|
| U.S. | FDA | NDA via CDER | Requires demonstration of efficacy, safety, and manufacturing quality (26% success rate for dermatologic drugs) |
| EU | EMA | CHMP review | Similar to FDA, with specific guidelines on phototherapy agents |
| Japan | PMDA | Shonin-sho approval | Emphasizes clinical efficacy and post-marketing surveillance |
Market Approval & Commercialization
- Psoralens are marketed mainly as compounded formulations; branded products are limited.
- Patent expirations are opening opportunities for generics.
- Novel formulations with patented delivery systems offer premium pricing potential.
Competitive Landscape
| Key Players | Market Share | Strategic Focus | Notable Patents |
|---|---|---|---|
| LEO Pharma | ~35% | Topical formulations, phototherapy | Patents on controlled UVA delivery systems |
| Merck Sharp & Dohme (MSD) | ~25% | Derivatives & combination regimens | Derivatives with improved safety profiles |
| Bausch Health (formerly Valeant) | ~15% | Combination therapies | Patents on multi-agent topical treatments |
| Innovator Startups | <10% | Nanocarriers, sustained release | Several granted patents from 2018–2023 |
| Generics | Varied | Cost-effective formulations | Filing recent patents for biosimilar equivalents |
Future Market Outlook
| Projection Parameters | 2023–2030 | Key Drivers |
|---|---|---|
| Market Valuation | USD 250–400 million | Increasing prevalence of psoriasis, expanding topical use |
| CAGR | 6–8% | Innovation in drug delivery, patent expirations, regulatory incentives |
| Innovation Focus | High | Derivative compounds, nanotechnology, combination therapies |
| Regulatory & Patent Strategy | Vital | Early filings, patent thickets, patent chaining to extend exclusivity |
Comparison of Psoralens with Alternative Therapies
| Attribute | Psoralens (D05AD) | Biologics | Topical Steroids |
|---|---|---|---|
| Efficacy | High in localized cases | Very high, systemic impact | Moderate, symptomatic relief |
| Safety Profile | Phototoxicity concerns | Immunosuppression risks | Skin atrophy, systemic absorption |
| Cost | Moderate | High | Low |
| Regulatory Complexity | Moderate | High | Low |
| Patent Life | Expiring, generics emerging | Strong, but limited by biosimilar competition | Widely available |
FAQs
1. What are the primary indications for psoralens in topical use?
Psoralens are primarily indicated for psoriasis, vitiligo, atopic dermatitis, and cutaneous T-cell lymphoma when used in conjunction with UVA phototherapy.
2. How does the patent landscape influence emerging competitors?
Patent expirations worldwide open the market to generics, but strategic filing of new formulations, derivatives, or delivery methods remain crucial for innovators to maintain competitive advantage.
3. What novel technologies are being integrated with psoralens?
Nanocarrier systems, controlled-release formulations, combination therapies with biologics, and advanced UVA delivery devices dominate recent patent filings.
4. How do regulatory pathways vary across regions?
While the overall process includes efficacy and safety assessments, EU and US regulators require specific phototherapy-related data. Differences in approval timelines and datasets influence market entry strategies.
5. What are the key challenges facing the psoralen topical market?
Phototoxicity, systemic absorption risks, regulatory hurdles, competition from biologics and new modalities, and patent challenges are ongoing issues.
Key Takeaways
- Market Growth: The psoralen topical segment is poised for steady growth driven by innovation and increasing demand for non-systemic dermatology treatments.
- Patent Strategy: Active patent filings focus on derivatives, advanced formulations, and delivery systems, with expirations shaping market entry.
- Regulatory Navigation: Success hinges on demonstrating safety, efficacy, and manufacturing quality adhering to regional frameworks.
- Innovation Opportunities: Nanotechnology, combination therapies, and personalized phototherapy protocols represent fertile grounds for product development.
- Competitive Strategy: Key players leverage patent portfolios, collaborations, and regional expansion to solidify market presence.
References
- World Health Organization. "Global prevalence of psoriasis." 2021.
- European Medicines Agency. “Guidelines on dermatological therapies,” 2022.
- PatentScope. WIPO. “Patent filings related to psoralen formulations,” 2010-2023.
- IQVIA. “Dermatology market analysis,” 2022.
- FDA. “Regulatory considerations for topical dermatological therapies,” 2023.
Disclaimer: This analysis is based on publicly available information as of August 2023. Patent statuses and market dynamics are subject to change with ongoing developments.
More… ↓
